Clinical trial
A Phase I/II Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70.
NCT01813539 is registered in ClinicalTrials.gov with OncoVerity, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70.
- Lead sponsor
- OncoVerity, Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- February 27, 2013
- Completion date
- July 10, 2020
- Enrollment
- 99 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.